FindTrial
Sign In

Clinical Study on FBLN3-Induced Gemcitabine Resistance in Pancreatic Cancer

Clinical Study on FBLN3-Induced Gemcitabine Resistance in Pancreatic Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118299
Enrollment
Unknown
Registered
2026-02-04
Start date
2025-11-14
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

Based on the response to gemcitabine chemotherapy, patients are divided into Gemcitabine-Resistant Group and Gemcitabine-Sensitive Group:NA

Sponsors

Fifth Affiliated Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Pathologically confirmed pancreatic ductal adenocarcinoma (PDAC); 2. Availability of tumor tissue specimens; 3. Complete clinical medical records; 4. Receipt of a gemcitabine-based chemotherapy regimen.

Exclusion criteria

Exclusion criteria: If they meet any of the following conditions, they will be excluded from this study: 1. Presence of other malignancies; 2. Unavailability of reliable tissue specimens; 3. Incomplete information on chemotherapy or clinical outcomes.

Design outcomes

Primary

MeasureTime frame
CA-199 level;Changes in tumor size or presence of metastasis;—

Countries

China

Contacts

Public ContactXu Yuchun

Fifth Affiliated Hospital, Sun Yat-Sen University

xuyuchun33@163.com+86 756 2528841

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026